Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

Therefore, new therapeutic or strategies already available for treatment of CDI have two goals: eradicating the infection, despite the continuation of concomitant therapy, and reducing the ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

She led CDC activities to detect and prevent infections in healthcare settings ... and developing innovative microbiome therapeutics and treatments for inflammatory bowel disease (IBD).

H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Here’s our process. If you’re managing a sexually transmitted infection (STI), you have options for treatment. While you can visit a healthcare professional in person for an evaluation and ...

The U.S. Food and Drug Administration has approved Zevra Therapeutics' Miplyffa (arimoclomol), an oral medication for the ...

Clostridium difficile infection (CDI) is considered to be the ... Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical ...